Free Trial

PROCEPT BioRobotics (PRCT) Financials

PROCEPT BioRobotics logo
$58.53 +1.15 (+2.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$58.98 +0.45 (+0.76%)
As of 05/27/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for PROCEPT BioRobotics

Annual Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders
-91 -106 -87 -60 -53
Consolidated Net Income / (Loss)
-91 -106 -87 -60 -53
Net Income / (Loss) Continuing Operations
-91 -106 -87 -60 -53
Total Pre-Tax Income
-91 -106 -87 -60 -53
Total Operating Income
-97 -109 -81 -54 -48
Total Gross Profit
137 71 37 16 -1.26
Total Revenue
224 136 75 34 7.72
Operating Revenue
224 136 75 34 -
Total Cost of Revenue
87 65 38 19 8.97
Operating Cost of Revenue
87 65 38 19 8.97
Total Operating Expenses
234 180 118 70 47
Selling, General & Admin Expense
171 132 89 51 30
Research & Development Expense
62 48 29 19 16
Total Other Income / (Expense), net
5.20 3.27 -6.43 -5.69 -5.22
Interest Expense
4.18 4.00 8.44 5.81 5.26
Other Income / (Expense), net
9.39 7.27 2.01 0.12 0.04
Basic Earnings per Share
($1.75) ($2.24) ($1.96) ($3.63) ($14.47)
Weighted Average Basic Shares Outstanding
52.13M 47.26M 44.40M 16.48M 3.66M
Diluted Earnings per Share
($1.75) ($2.24) ($1.96) ($3.63) ($14.47)
Weighted Average Diluted Shares Outstanding
52.13M 47.26M 44.40M 16.48M 3.66M
Weighted Average Basic & Diluted Shares Outstanding
54.82M 50.96M 44.87M 43.99M -

Quarterly Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Consolidated Net Income / (Loss)
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Net Income / (Loss) Continuing Operations
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Total Pre-Tax Income
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Total Operating Income
-27 -20 -22 -27 -28 -30 -26 -26 -28 -25 -22
Total Gross Profit
44 44 37 31 25 21 19 18 12 11 10
Total Revenue
69 68 58 53 45 44 35 33 24 24 20
Operating Revenue
69 68 58 53 45 44 35 33 24 24 20
Total Cost of Revenue
25 25 21 22 20 22 16 15 12 13 10
Operating Cost of Revenue
25 25 21 22 20 22 16 15 12 13 10
Total Operating Expenses
72 63 59 58 53 51 44 44 41 36 32
Selling, General & Admin Expense
55 48 43 41 40 36 33 32 30 26 25
Research & Development Expense
16 15 17 18 13 14 12 12 11 9.68 7.58
Total Other Income / (Expense), net
2.70 0.85 1.45 1.20 1.69 2.05 0.99 0.34 -0.11 -3.13 -0.51
Interest Expense
0.88 0.97 1.14 1.03 1.05 1.13 1.02 0.97 0.89 4.12 1.46
Other Income / (Expense), net
3.58 1.82 2.59 2.23 2.74 3.18 2.01 1.31 0.78 0.99 0.95
Basic Earnings per Share
($0.45) ($0.34) ($0.40) ($0.50) ($0.51) ($0.54) ($0.51) ($0.56) ($0.63) ($0.63) ($0.51)
Weighted Average Basic Shares Outstanding
54.92M 52.13M 52.01M 51.62M 51.01M 47.26M 48.31M 45.16M 45.07M 44.40M 44.64M
Diluted Earnings per Share
($0.45) ($0.34) ($0.40) ($0.50) ($0.51) ($0.54) ($0.51) ($0.56) ($0.63) ($0.63) ($0.51)
Weighted Average Diluted Shares Outstanding
54.92M 52.13M 52.01M 51.62M 51.01M 47.26M 48.31M 45.16M 45.07M 44.40M 44.64M
Weighted Average Basic & Diluted Shares Outstanding
55.33M 54.82M 52.18M 51.93M 51.42M 50.96M 50.50M 45.28M 45.05M 44.87M 44.72M

Annual Cash Flow Statements for PROCEPT BioRobotics

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents
77 35 -79 204 58
Net Cash From Operating Activities
-99 -108 -80 -57 -48
Net Cash From Continuing Operating Activities
-99 -108 -80 -57 -48
Net Income / (Loss) Continuing Operations
-91 -106 -87 -60 -53
Consolidated Net Income / (Loss)
-91 -106 -87 -60 -53
Depreciation Expense
5.23 3.81 2.84 - 2.86
Non-Cash Adjustments To Reconcile Net Income
34 25 15 3.90 2.30
Changes in Operating Assets and Liabilities, net
-47 -31 -11 -4.71 -0.48
Net Cash From Investing Activities
-4.41 -25 -2.65 -0.59 -0.23
Net Cash From Continuing Investing Activities
-4.41 -25 -2.65 -0.59 -0.23
Purchase of Property, Plant & Equipment
-4.41 -25 -2.65 -0.59 -0.23
Net Cash From Financing Activities
180 168 3.61 262 107
Net Cash From Continuing Financing Activities
180 168 3.61 262 107
Repayment of Debt
0.00 0.00 -51 0.00 -
Issuance of Debt
4.53 3.61 54 0.00 25
Issuance of Common Equity
165 162 0.00 172 0.00
Other Financing Activities, net
11 2.48 1.01 5.04 5.60
Cash Interest Paid
3.97 4.06 4.29 4.75 3.97

Quarterly Cash Flow Statements for PROCEPT BioRobotics

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-18 137 -17 -11 -32 -31 137 -31 -41 -27 -21
Net Cash From Operating Activities
-17 -32 -19 -16 -32 -25 -19 -28 -36 -25 -20
Net Cash From Continuing Operating Activities
-17 -32 -19 -16 -32 -25 -19 -28 -36 -25 -20
Net Income / (Loss) Continuing Operations
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Consolidated Net Income / (Loss)
-25 -19 -21 -26 -26 -28 -25 -25 -28 -28 -23
Depreciation Expense
1.48 1.45 1.33 1.27 1.18 1.32 1.05 0.64 0.79 0.66 0.70
Non-Cash Adjustments To Reconcile Net Income
11 7.38 9.25 8.80 8.76 4.87 5.72 6.88 7.66 6.95 4.15
Changes in Operating Assets and Liabilities, net
-4.33 -22 -8.40 -0.18 -16 -3.48 -1.09 -11 -16 -4.62 -2.09
Net Cash From Investing Activities
-1.84 -1.17 -0.25 -1.04 -1.95 -8.72 -5.78 -5.37 -5.34 -0.87 -1.51
Net Cash From Continuing Investing Activities
-1.84 -1.17 -0.25 -1.04 -1.95 -8.72 -5.78 -5.37 -5.34 -0.87 -1.51
Purchase of Property, Plant & Equipment
-1.84 -1.17 -0.25 -1.04 -1.95 -8.72 -5.78 -5.37 -5.34 -0.87 -1.51
Net Cash From Financing Activities
1.30 171 1.72 5.30 2.59 2.87 162 2.43 0.38 -1.32 0.78
Net Cash From Continuing Financing Activities
1.30 171 1.72 5.30 2.59 2.87 162 2.43 0.38 -1.32 0.78
Other Financing Activities, net
1.30 3.60 1.72 3.17 2.59 0.97 0.41 0.71 0.38 -2.63 0.78
Cash Interest Paid
0.89 0.92 1.01 1.03 1.00 1.00 0.99 0.94 1.12 0.72 1.20

Annual Balance Sheets for PROCEPT BioRobotics

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets
534 405 309 337 126
Total Current Assets
482 351 273 326 110
Cash & Equivalents
334 257 222 304 100
Accounts Receivable
83 48 15 4.46 1.55
Inventories, net
56 40 29 13 6.92
Prepaid Expenses
8.45 5.21 6.18 4.24 1.65
Plant, Property, & Equipment, net
27 29 8.66 5.05 8.27
Total Noncurrent Assets
25 25 28 5.81 7.44
Goodwill
0.93 1.20 1.48 1.75 2.02
Other Noncurrent Operating Assets
25 24 27 4.06 5.42
Total Liabilities & Shareholders' Equity
534 405 309 337 126
Total Liabilities
132 124 112 70 65
Total Current Liabilities
53 46 35 16 15
Accounts Payable
10 13 9.39 2.03 1.24
Accrued Expenses
22 17 13 6.48 4.64
Current Deferred Revenue
9.57 5.66 2.86 1.03 0.23
Other Current Liabilities
12 9.89 9.60 6.71 3.86
Total Noncurrent Liabilities
79 78 77 54 50
Long-Term Debt
51 51 51 50 44
Other Noncurrent Operating Liabilities
27 27 26 3.69 6.08
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
402 281 197 267 -183
Total Preferred & Common Equity
402 281 197 267 -183
Preferred Stock
0.00 0.00 0.00 0.00 0.00
Total Common Equity
402 281 197 267 -183
Common Stock
948 735 546 529 19
Retained Earnings
-546 -455 -349 -262 -202
Accumulated Other Comprehensive Income / (Loss)
0.11 0.08 -0.01 -0.05 -0.01

Quarterly Balance Sheets for PROCEPT BioRobotics

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
519 374 374 383 421 272 284 324
Total Current Assets
466 323 322 329 369 230 246 289
Cash & Equivalents
316 197 214 226 287 150 181 249
Accounts Receivable
79 69 59 56 35 33 21 13
Inventories, net
62 51 44 42 42 43 39 22
Prepaid Expenses
7.99 6.32 5.02 5.91 3.98 3.74 4.26 4.52
Plant, Property, & Equipment, net
28 27 28 28 27 16 12 5.12
Total Noncurrent Assets
25 25 25 25 25 26 27 30
Goodwill
0.86 1.00 1.07 1.14 1.27 1.34 1.41 1.55
Other Noncurrent Operating Assets
25 24 24 24 24 25 26 28
Total Liabilities & Shareholders' Equity
519 374 374 383 421 272 284 324
Total Liabilities
130 133 123 119 122 117 111 103
Total Current Liabilities
52 54 43 39 41 36 33 27
Short-Term Debt
1.98 - - 1.70 - - 3.00 2.47
Accounts Payable
15 15 9.95 10 14 10 10 6.33
Accrued Expenses
15 19 15 11 13 9.95 7.41 10
Current Deferred Revenue
9.80 7.99 6.55 5.86 5.01 4.72 3.94 2.34
Other Current Liabilities
10 12 11 9.54 9.49 11 7.81 5.93
Total Noncurrent Liabilities
78 79 80 80 80 81 79 76
Long-Term Debt
51 51 51 51 51 51 51 51
Other Noncurrent Operating Liabilities
27 28 28 29 29 29 28 25
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
389 241 252 264 299 156 173 221
Total Preferred & Common Equity
389 241 252 264 299 156 173 221
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
389 241 252 264 299 156 173 221
Common Stock
960 768 758 744 726 558 550 541
Retained Earnings
-571 -527 -506 -481 -427 -402 -377 -321
Accumulated Other Comprehensive Income / (Loss)
0.22 -0.02 -0.00 0.11 -0.01 -0.01 0.02 0.22

Annual Metrics And Ratios for PROCEPT BioRobotics

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics
- - - - -
Revenue Growth
64.84% 81.55% 117.60% 346.72% 0.00%
EBITDA Growth
16.41% -29.29% -49.59% -12.96% 0.00%
EBIT Growth
14.40% -29.46% -45.65% -13.16% 0.00%
NOPAT Growth
11.50% -35.24% -49.04% -13.31% 0.00%
Net Income Growth
13.68% -21.51% -45.61% -12.89% 0.00%
EPS Growth
21.88% -14.29% 46.01% 74.91% 0.00%
Operating Cash Flow Growth
8.14% -34.36% -40.20% -18.60% 0.00%
Free Cash Flow Firm Growth
10.28% -81.09% -69.63% 0.00% 0.00%
Invested Capital Growth
60.24% 191.90% 100.78% 30.52% 0.00%
Revenue Q/Q Growth
12.34% 17.02% 22.22% 0.00% 0.00%
EBITDA Q/Q Growth
14.34% 1.48% -6.01% 0.00% 0.00%
EBIT Q/Q Growth
8.87% -2.34% -9.98% 0.00% 0.00%
NOPAT Q/Q Growth
9.25% -4.32% -11.32% 0.00% 0.00%
Net Income Q/Q Growth
8.64% 0.63% -12.70% 0.00% 0.00%
EPS Q/Q Growth
10.26% 3.86% -229.80% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-8.29% 0.35% -12.13% -5.58% 0.00%
Free Cash Flow Firm Q/Q Growth
-4.75% -12.84% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
25.10% 19.22% 3.80% 0.00% 0.00%
Profitability Metrics
- - - - -
Gross Margin
61.07% 52.17% 49.44% 46.02% -16.26%
EBITDA Margin
-36.52% -72.03% -101.14% -147.13% -581.81%
Operating Margin
-43.04% -80.16% -107.61% -157.12% -619.44%
EBIT Margin
-38.86% -74.82% -104.93% -156.77% -618.87%
Profit (Net Income) Margin
-40.72% -77.76% -116.18% -173.62% -687.04%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
104.80% 103.92% 110.72% 110.75% 111.02%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-69.42% -152.05% -294.12% -336.08% -341.86%
ROIC Less NNEP Spread (ROIC-NNEP)
-59.68% -136.42% -279.73% -321.72% -303.64%
Return on Net Nonoperating Assets (RNNOA)
42.65% 107.73% 256.57% 299.59% 254.89%
Return on Equity (ROE)
-26.77% -44.32% -37.55% -36.49% -86.97%
Cash Return on Invested Capital (CROIC)
-115.72% -249.98% -361.13% -362.56% 0.00%
Operating Return on Assets (OROA)
-18.58% -28.54% -24.36% -23.35% -37.91%
Return on Assets (ROA)
-19.48% -29.66% -26.97% -25.85% -42.09%
Return on Common Equity (ROCE)
-26.77% -44.32% -37.55% -9.37% 260.94%
Return on Equity Simple (ROE_SIMPLE)
-22.73% -37.72% -44.22% -22.41% 28.99%
Net Operating Profit after Tax (NOPAT)
-68 -76 -57 -38 -33
NOPAT Margin
-30.12% -56.11% -75.33% -109.98% -433.61%
Net Nonoperating Expense Percent (NNEP)
-9.74% -15.63% -14.40% -14.36% -38.22%
Return On Investment Capital (ROIC_SIMPLE)
-14.91% -23.01% -22.76% - -
Cost of Revenue to Revenue
38.93% 47.83% 50.56% 53.98% 116.26%
SG&A Expenses to Revenue
76.35% 96.76% 118.42% 148.05% 392.28%
R&D to Revenue
27.75% 35.57% 38.63% 55.10% 210.90%
Operating Expenses to Revenue
104.10% 132.33% 157.05% 203.14% 603.17%
Earnings before Interest and Taxes (EBIT)
-87 -102 -79 -54 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-82 -98 -76 -51 -45
Valuation Ratios
- - - - -
Price to Book Value (P/BV)
10.45 7.54 9.43 4.07 0.00
Price to Tangible Book Value (P/TBV)
10.47 7.57 9.50 4.10 0.00
Price to Revenue (P/Rev)
18.72 15.54 24.76 31.56 17.82
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
32.67 25.52 65.74 65.25 33.73
Enterprise Value to Revenue (EV/Rev)
17.46 14.03 22.48 24.18 42.79
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - -
Debt to Equity
0.13 0.18 0.26 0.19 0.80
Long-Term Debt to Equity
0.13 0.18 0.26 0.19 0.73
Financial Leverage
-0.71 -0.79 -0.92 -0.93 -0.84
Leverage Ratio
1.37 1.49 1.39 1.41 2.07
Compound Leverage Factor
1.44 1.55 1.54 1.56 2.29
Debt to Total Capital
11.35% 15.46% 20.63% 15.77% 44.54%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 4.14%
Long-Term Debt to Total Capital
11.35% 15.46% 20.63% 15.77% 40.40%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 221.85%
Common Equity to Total Capital
88.65% 84.54% 79.37% 84.23% -166.39%
Debt to EBITDA
-0.63 -0.52 -0.68 -0.99 -1.09
Net Debt to EBITDA
3.44 2.10 2.26 5.01 1.14
Long-Term Debt to EBITDA
-0.63 -0.52 -0.68 -0.99 -0.99
Debt to NOPAT
-0.76 -0.67 -0.91 -1.32 -1.46
Net Debt to NOPAT
4.17 2.69 3.03 6.71 1.53
Long-Term Debt to NOPAT
-0.76 -0.67 -0.91 -1.32 -1.33
Altman Z-Score
18.54 9.08 8.67 8.92 -1.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 74.33% 400.02%
Liquidity Ratios
- - - - -
Current Ratio
9.07 7.63 7.73 20.08 7.59
Quick Ratio
7.85 6.65 6.72 19.01 7.00
Cash Flow Metrics
- - - - -
Free Cash Flow to Firm (FCFF)
-113 -126 -69 -41 0.00
Operating Cash Flow to CapEx
-2,250.24% -428.48% -3,029.85% -9,684.80% -20,748.07%
Free Cash Flow to Firm to Interest Expense
-26.94 -31.45 -8.22 -7.04 0.00
Operating Cash Flow to Interest Expense
-23.71 -27.03 -9.52 -9.87 -9.19
Operating Cash Flow Less CapEx to Interest Expense
-24.77 -33.34 -9.84 -9.97 -9.23
Efficiency Ratios
- - - - -
Asset Turnover
0.48 0.38 0.23 0.15 0.06
Accounts Receivable Turnover
3.40 4.28 7.60 11.47 4.98
Inventory Turnover
1.82 1.91 1.82 1.85 1.30
Fixed Asset Turnover
8.10 7.28 10.95 5.18 0.93
Accounts Payable Turnover
7.43 5.69 6.64 11.38 7.24
Days Sales Outstanding (DSO)
107.20 85.29 48.02 31.83 73.26
Days Inventory Outstanding (DIO)
200.30 191.34 200.60 196.85 281.68
Days Payable Outstanding (DPO)
49.14 64.13 54.95 32.06 50.45
Cash Conversion Cycle (CCC)
258.37 212.51 193.66 196.62 304.50
Capital & Investment Metrics
- - - - -
Invested Capital
120 75 26 13 9.79
Invested Capital Turnover
2.30 2.71 3.90 3.06 0.79
Increase / (Decrease) in Invested Capital
45 49 13 2.99 0.00
Enterprise Value (EV)
3,920 1,911 1,686 834 330
Market Capitalization
4,202 2,116 1,858 1,088 138
Book Value per Share
$7.71 $5.56 $4.41 $6.14 ($49.93)
Tangible Book Value per Share
$7.69 $5.54 $4.37 $6.10 ($50.48)
Total Capital
454 332 248 317 110
Total Debt
51 51 51 50 49
Total Long-Term Debt
51 51 51 50 44
Net Debt
-282 -206 -171 -254 -51
Capital Expenditures (CapEx)
4.41 25 2.65 0.59 0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)
95 47 15 5.61 0.15
Debt-free Net Working Capital (DFNWC)
429 305 237 310 100
Net Working Capital (NWC)
429 305 237 310 96
Net Nonoperating Expense (NNE)
24 29 31 22 20
Net Nonoperating Obligations (NNO)
-282 -206 -171 -254 -51
Total Depreciation and Amortization (D&A)
5.23 3.81 2.84 3.32 2.86
Debt-free, Cash-free Net Working Capital to Revenue
42.31% 34.82% 19.60% 16.28% 1.96%
Debt-free Net Working Capital to Revenue
190.96% 223.69% 316.39% 899.05% 1,299.48%
Net Working Capital to Revenue
190.96% 223.69% 316.39% 899.05% 1,240.51%
Earnings Adjustments
- - - - -
Adjusted Basic Earnings per Share
($1.75) ($2.24) ($1.96) ($3.63) $0.00
Adjusted Weighted Average Basic Shares Outstanding
52.13M 47.26M 44.40M 16.48M 0.00
Adjusted Diluted Earnings per Share
($1.75) ($2.24) ($1.96) ($3.63) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
52.13M 47.26M 44.40M 16.48M 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
54.82M 50.96M 44.87M 43.99M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-68 -76 -57 -38 -33
Normalized NOPAT Margin
-30.12% -56.11% -75.33% -109.98% -433.61%
Pre Tax Income Margin
-40.72% -77.76% -116.18% -173.62% -687.04%
Debt Service Ratios
- - - - -
EBIT to Interest Expense
-20.85 -25.51 -9.33 -9.30 -9.08
NOPAT to Interest Expense
-16.16 -19.13 -6.69 -6.53 -6.36
EBIT Less CapEx to Interest Expense
-21.90 -31.82 -9.64 -9.40 -9.12
NOPAT Less CapEx to Interest Expense
-17.22 -25.44 -7.01 -6.63 -6.40
Payout Ratios
- - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PROCEPT BioRobotics

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
55.28% 56.57% 66.29% 61.17% 82.51% 83.29% 72.50% 98.33% 71.90% 134.56% 134.76%
EBITDA Growth
5.66% 34.43% 17.93% 1.48% 11.48% -7.18% -10.24% -39.07% -78.63% -38.32% -72.79%
EBIT Growth
4.22% 32.20% 15.97% -1.13% 9.73% -9.70% -11.56% -37.07% -75.07% -42.24% -67.47%
NOPAT Growth
0.76% 33.32% 12.43% -4.69% 2.57% -18.05% -15.85% -43.36% -80.70% -48.77% -72.74%
Net Income Growth
4.70% 31.45% 14.82% -1.35% 8.87% 2.36% -8.88% -31.80% -65.75% -53.54% -60.34%
EPS Growth
11.76% 37.04% 21.57% 10.71% 19.05% 14.29% 0.00% -30.23% -61.54% -122.18% 58.20%
Operating Cash Flow Growth
47.41% -30.65% 0.75% 44.47% 10.14% 1.51% 4.57% -65.47% -97.07% -52.79% -55.68%
Free Cash Flow Firm Growth
17.14% 15.76% 12.89% 2.55% -39.60% -129.96% -103.00% -51.47% -57.41% 0.00% -28.06%
Invested Capital Growth
38.11% 60.24% 52.70% 57.10% 100.68% 191.90% 154.14% 156.06% 143.73% 100.78% 96.27%
Revenue Q/Q Growth
1.36% 16.90% 9.40% 19.79% 2.20% 24.16% 6.04% 35.65% 2.64% 16.85% 21.92%
EBITDA Q/Q Growth
-36.21% 11.20% 20.67% 1.69% 10.06% -11.15% 4.77% 11.67% -11.46% -14.32% -20.14%
EBIT Q/Q Growth
-33.39% 9.82% 19.36% 1.27% 5.57% -11.77% 2.95% 11.88% -14.76% -13.66% -19.25%
NOPAT Q/Q Growth
-39.21% 12.11% 16.40% 2.97% 6.46% -15.42% 0.06% 9.70% -13.33% -13.28% -23.66%
Net Income Q/Q Growth
-31.19% 10.10% 18.15% 1.28% 5.63% -11.71% 2.62% 11.23% -1.11% -24.58% -17.87%
EPS Q/Q Growth
-32.35% 15.00% 20.00% 1.96% 5.56% -5.88% 8.93% 11.11% 0.00% -23.53% -18.60%
Operating Cash Flow Q/Q Growth
47.58% -72.29% -19.47% 51.26% -30.22% -30.88% 33.16% 21.12% -42.72% -26.81% -15.91%
Free Cash Flow Firm Q/Q Growth
8.15% -20.70% 4.63% 21.63% 6.62% -24.81% -6.70% -12.27% -53.82% -10.18% 20.39%
Invested Capital Q/Q Growth
5.39% 25.10% 7.64% -2.68% 22.27% 19.22% 10.74% 24.32% 77.85% 3.80% 11.57%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
63.85% 64.00% 63.24% 59.01% 56.21% 48.77% 53.77% 55.67% 51.18% 44.90% 50.28%
EBITDA Margin
-32.37% -24.08% -31.70% -43.72% -53.27% -57.51% -64.24% -71.53% -109.84% -98.35% -100.52%
Operating Margin
-39.67% -28.89% -38.42% -50.28% -62.08% -67.83% -72.96% -77.41% -116.28% -105.31% -108.63%
EBIT Margin
-34.50% -26.21% -33.98% -46.10% -55.93% -60.53% -67.24% -73.47% -113.09% -101.14% -103.98%
Profit (Net Income) Margin
-35.77% -27.63% -35.93% -48.03% -58.28% -63.11% -70.14% -76.38% -116.72% -118.48% -111.13%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
103.68% 105.42% 105.75% 104.19% 104.19% 104.26% 104.32% 103.97% 103.21% 117.15% 106.88%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-63.48% -46.60% -67.74% -85.26% -99.05% -128.65% -135.84% -139.67% -215.65% -287.84% -250.24%
ROIC Less NNEP Spread (ROIC-NNEP)
-60.94% -44.52% -64.98% -80.03% -94.65% -125.04% -132.75% -135.03% -210.88% -282.84% -247.18%
Return on Net Nonoperating Assets (RNNOA)
40.60% 31.82% 45.90% 51.41% 64.96% 98.74% 110.41% 108.08% 179.03% 259.42% 228.89%
Return on Equity (ROE)
-22.88% -14.77% -21.84% -33.85% -34.10% -29.92% -25.43% -31.60% -36.62% -28.41% -21.35%
Cash Return on Invested Capital (CROIC)
-93.93% -115.72% -135.63% -149.70% -177.66% -249.98% -254.48% -267.23% -286.88% -361.13% 0.00%
Operating Return on Assets (OROA)
-19.05% -12.54% -17.08% -25.17% -26.20% -23.09% -21.00% -25.60% -31.84% -23.48% -18.89%
Return on Assets (ROA)
-19.75% -13.22% -18.06% -26.22% -27.30% -24.08% -21.91% -26.61% -32.86% -27.50% -20.19%
Return on Common Equity (ROCE)
-22.88% -14.77% -21.84% -33.85% -34.10% -29.92% -25.43% -31.60% -36.62% -28.41% -21.35%
Return on Equity Simple (ROE_SIMPLE)
-23.18% 0.00% -41.48% -41.19% -39.15% 0.00% -35.60% -67.06% -56.87% 0.00% -35.03%
Net Operating Profit after Tax (NOPAT)
-19 -14 -16 -19 -19 -21 -18 -18 -20 -18 -15
NOPAT Margin
-27.77% -20.22% -26.90% -35.20% -43.45% -47.48% -51.07% -54.19% -81.40% -73.72% -76.04%
Net Nonoperating Expense Percent (NNEP)
-2.54% -2.07% -2.76% -5.23% -4.40% -3.61% -3.10% -4.65% -4.77% -5.00% -3.06%
Return On Investment Capital (ROIC_SIMPLE)
-4.34% -3.04% - - - -6.23% - - - -7.06% -
Cost of Revenue to Revenue
36.15% 36.00% 36.76% 40.99% 43.79% 51.23% 46.23% 44.33% 48.82% 55.10% 49.72%
SG&A Expenses to Revenue
79.81% 70.81% 73.14% 76.49% 88.91% 83.33% 93.68% 98.00% 123.47% 109.49% 121.65%
R&D to Revenue
23.72% 22.08% 28.52% 32.80% 29.38% 33.26% 33.05% 35.08% 44.00% 40.72% 37.26%
Operating Expenses to Revenue
103.52% 92.89% 101.66% 109.29% 118.29% 116.60% 126.73% 133.08% 167.46% 150.21% 158.91%
Earnings before Interest and Taxes (EBIT)
-24 -18 -20 -25 -25 -26 -24 -24 -28 -24 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-22 -16 -19 -23 -24 -25 -23 -24 -27 -23 -20
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
8.21 10.45 17.25 12.48 9.45 7.54 4.96 10.21 7.36 9.43 8.37
Price to Tangible Book Value (P/TBV)
8.23 10.47 17.32 12.53 9.49 7.57 4.98 10.30 7.42 9.50 8.43
Price to Revenue (P/Rev)
12.82 18.72 20.82 17.79 15.96 15.54 12.76 15.67 14.95 24.76 30.12
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
23.18 32.67 41.87 33.44 25.38 25.52 19.89 26.33 25.14 65.74 66.89
Enterprise Value to Revenue (EV/Rev)
11.77 17.46 20.09 16.87 14.86 14.03 10.73 14.69 13.46 22.48 26.93
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.14 0.13 0.21 0.20 0.20 0.18 0.17 0.33 0.31 0.26 0.24
Long-Term Debt to Equity
0.13 0.13 0.21 0.20 0.19 0.18 0.17 0.33 0.30 0.26 0.23
Financial Leverage
-0.67 -0.71 -0.71 -0.64 -0.69 -0.79 -0.83 -0.80 -0.85 -0.92 -0.93
Leverage Ratio
1.38 1.37 1.47 1.59 1.53 1.49 1.43 1.48 1.42 1.39 1.34
Compound Leverage Factor
1.43 1.45 1.56 1.65 1.59 1.56 1.49 1.54 1.47 1.63 1.43
Debt to Total Capital
12.08% 11.35% 17.58% 16.95% 16.74% 15.46% 14.63% 24.75% 23.86% 20.63% 19.41%
Short-Term Debt to Total Capital
0.45% 0.00% 0.00% 0.00% 0.54% 0.00% 0.00% 0.00% 1.32% 0.00% 0.90%
Long-Term Debt to Total Capital
11.63% 11.35% 17.58% 16.95% 16.20% 15.46% 14.63% 24.75% 22.54% 20.63% 18.51%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
87.92% 88.65% 82.42% 83.05% 83.26% 84.54% 85.37% 75.25% 76.14% 79.37% 80.59%
Debt to EBITDA
-0.66 -0.63 -0.54 -0.52 -0.53 -0.52 -0.52 -0.53 -0.60 -0.68 -0.74
Net Debt to EBITDA
3.26 3.44 1.52 1.64 1.74 2.10 2.38 1.02 1.41 2.26 2.74
Long-Term Debt to EBITDA
-0.64 -0.63 -0.54 -0.52 -0.52 -0.52 -0.52 -0.53 -0.57 -0.68 -0.71
Debt to NOPAT
-0.79 -0.76 -0.69 -0.67 -0.70 -0.67 -0.70 -0.72 -0.83 -0.91 -1.05
Net Debt to NOPAT
3.89 4.17 1.95 2.12 2.27 2.69 3.23 1.40 1.95 3.03 3.86
Long-Term Debt to NOPAT
-0.76 -0.76 -0.69 -0.67 -0.68 -0.67 -0.70 -0.72 -0.78 -0.91 -1.00
Altman Z-Score
14.46 18.97 18.03 14.63 11.95 9.70 6.92 7.06 5.89 9.26 10.30
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
8.95 9.07 6.02 7.51 8.52 7.63 8.91 6.40 7.56 7.73 10.56
Quick Ratio
7.60 7.85 4.95 6.37 7.29 6.65 7.78 5.09 6.20 6.72 9.58
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-54 -59 -49 -51 -65 -70 -56 -52 -47 -30 -28
Operating Cash Flow to CapEx
-924.84% -2,759.03% -7,642.28% -1,508.72% -1,659.10% -284.49% -327.73% -527.53% -672.94% -2,906.93% -1,311.16%
Free Cash Flow to Firm to Interest Expense
-61.68 -60.78 -42.80 -49.67 -62.47 -62.14 -54.97 -54.40 -52.78 -7.37 -18.96
Operating Cash Flow to Interest Expense
-19.36 -33.43 -16.49 -15.28 -30.90 -22.04 -18.59 -29.37 -40.55 -6.10 -13.64
Operating Cash Flow Less CapEx to Interest Expense
-21.46 -34.64 -16.71 -16.29 -32.76 -29.78 -24.26 -34.93 -46.58 -6.31 -14.68
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.55 0.48 0.50 0.55 0.47 0.38 0.31 0.35 0.28 0.23 0.18
Accounts Receivable Turnover
3.68 3.40 3.86 3.83 4.08 4.28 4.90 4.61 6.17 7.60 6.40
Inventory Turnover
1.79 1.82 1.83 1.85 1.81 1.91 1.73 1.77 1.68 1.82 1.86
Fixed Asset Turnover
8.80 8.10 7.45 8.02 7.73 7.28 7.24 9.79 10.33 10.95 11.31
Accounts Payable Turnover
7.46 7.43 5.94 8.00 7.12 5.69 5.61 7.45 6.68 6.64 6.14
Days Sales Outstanding (DSO)
99.15 107.20 94.67 95.18 89.57 85.29 74.42 79.13 59.18 48.02 57.07
Days Inventory Outstanding (DIO)
204.22 200.30 199.41 197.50 202.11 191.34 210.71 206.71 217.11 200.60 196.34
Days Payable Outstanding (DPO)
48.94 49.14 61.47 45.63 51.25 64.13 65.04 49.02 54.61 54.95 59.46
Cash Conversion Cycle (CCC)
254.44 258.37 232.61 247.05 240.43 212.51 220.08 236.82 221.67 193.66 193.94
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
126 120 96 89 92 75 63 57 46 26 25
Invested Capital Turnover
2.29 2.30 2.52 2.42 2.28 2.71 2.66 2.58 2.65 3.90 3.29
Increase / (Decrease) in Invested Capital
35 45 33 32 46 49 38 35 27 13 12
Enterprise Value (EV)
2,931 3,920 4,015 2,979 2,323 1,911 1,249 1,493 1,147 1,686 1,653
Market Capitalization
3,194 4,202 4,161 3,142 2,496 2,116 1,486 1,592 1,274 1,858 1,849
Book Value per Share
$7.10 $7.71 $4.64 $4.88 $5.18 $5.56 $6.61 $3.46 $3.86 $4.41 $4.95
Tangible Book Value per Share
$7.08 $7.69 $4.63 $4.86 $5.15 $5.54 $6.58 $3.43 $3.83 $4.37 $4.92
Total Capital
443 454 293 303 317 332 351 207 227 248 274
Total Debt
53 51 51 51 53 51 51 51 54 51 53
Total Long-Term Debt
51 51 51 51 51 51 51 51 51 51 51
Net Debt
-263 -282 -145 -163 -173 -206 -237 -99 -128 -171 -196
Capital Expenditures (CapEx)
1.84 1.17 0.25 1.04 1.95 8.72 5.78 5.37 5.34 0.87 1.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)
100 95 73 65 67 47 39 44 34 15 15
Debt-free Net Working Capital (DFNWC)
416 429 269 279 292 305 327 194 216 237 264
Net Working Capital (NWC)
414 429 269 279 291 305 327 194 213 237 262
Net Nonoperating Expense (NNE)
5.53 5.06 5.28 6.85 6.60 6.81 6.70 7.35 8.62 11 7.14
Net Nonoperating Obligations (NNO)
-263 -282 -145 -163 -173 -206 -237 -99 -128 -171 -196
Total Depreciation and Amortization (D&A)
1.48 1.45 1.33 1.27 1.18 1.32 1.05 0.64 0.79 0.66 0.70
Debt-free, Cash-free Net Working Capital to Revenue
39.94% 42.31% 36.32% 36.79% 42.64% 34.82% 33.89% 42.90% 40.28% 19.60% 24.16%
Debt-free Net Working Capital to Revenue
166.87% 190.96% 134.77% 158.03% 186.94% 223.69% 281.23% 190.95% 253.55% 316.39% 430.22%
Net Working Capital to Revenue
166.07% 190.96% 134.77% 158.03% 185.85% 223.69% 281.23% 190.95% 250.03% 316.39% 426.20%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.45) ($0.34) ($0.40) ($0.50) ($0.51) ($0.54) ($0.51) ($0.56) ($0.63) ($0.63) ($0.51)
Adjusted Weighted Average Basic Shares Outstanding
54.92M 52.13M 52.01M 51.62M 51.01M 47.26M 48.31M 45.16M 45.07M 44.40M 44.64M
Adjusted Diluted Earnings per Share
($0.45) ($0.34) ($0.40) ($0.50) ($0.51) ($0.54) ($0.51) ($0.56) ($0.63) ($0.63) ($0.51)
Adjusted Weighted Average Diluted Shares Outstanding
54.92M 52.13M 52.01M 51.62M 51.01M 47.26M 48.31M 45.16M 45.07M 44.40M 44.64M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
55.33M 54.82M 52.18M 51.93M 51.42M 50.96M 50.50M 45.28M 45.05M 44.87M 44.72M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -14 -16 -19 -19 -21 -18 -18 -20 -18 -15
Normalized NOPAT Margin
-27.77% -20.22% -26.90% -35.20% -43.45% -47.48% -51.07% -54.19% -81.40% -73.72% -76.04%
Pre Tax Income Margin
-35.77% -27.63% -35.93% -48.03% -58.28% -63.11% -70.14% -76.38% -116.72% -118.48% -111.13%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-27.21 -18.46 -17.40 -23.88 -23.84 -23.45 -23.16 -25.20 -31.15 -5.83 -14.54
NOPAT to Interest Expense
-21.90 -14.24 -13.77 -18.23 -18.52 -18.39 -17.59 -18.59 -22.42 -4.25 -10.63
EBIT Less CapEx to Interest Expense
-29.30 -19.67 -17.61 -24.89 -25.70 -31.20 -28.84 -30.77 -37.17 -6.04 -15.58
NOPAT Less CapEx to Interest Expense
-23.99 -15.45 -13.99 -19.25 -20.38 -26.14 -23.26 -24.15 -28.45 -4.46 -11.68
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About PROCEPT BioRobotics' Financials

When does PROCEPT BioRobotics's financial year end?

According to the most recent income statement we have on file, PROCEPT BioRobotics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has PROCEPT BioRobotics' net income changed over the last 4 years?

PROCEPT BioRobotics' net income appears to be on an upward trend, with a most recent value of -$91.41 million in 2024, rising from -$53.02 million in 2020. The previous period was -$105.90 million in 2023. Check out PROCEPT BioRobotics' forecast to explore projected trends and price targets.

What is PROCEPT BioRobotics's operating income?
PROCEPT BioRobotics's total operating income in 2024 was -$96.61 million, based on the following breakdown:
  • Total Gross Profit: $137.10 million
  • Total Operating Expenses: $233.71 million
How has PROCEPT BioRobotics revenue changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' total revenue changed from $7.72 million in 2020 to $224.50 million in 2024, a change of 2,809.1%.

How much debt does PROCEPT BioRobotics have?

PROCEPT BioRobotics' total liabilities were at $131.80 million at the end of 2024, a 6.3% increase from 2023, and a 102.7% increase since 2020.

How much cash does PROCEPT BioRobotics have?

In the past 4 years, PROCEPT BioRobotics' cash and equivalents has ranged from $100.13 million in 2020 to $333.73 million in 2024, and is currently $333.73 million as of their latest financial filing in 2024.

How has PROCEPT BioRobotics' book value per share changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' book value per share changed from -49.93 in 2020 to 7.71 in 2024, a change of -115.4%.



This page (NASDAQ:PRCT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners